Invivyd (IVVD) Total Liabilities (2020 - 2025)
Invivyd posted quarterly Total Liabilities of $35.3 million for Q4 2025, down 42.97% year-on-year from $62.0 million in Q4 2024, and down 23.32% on a QoQ basis from $46.1 million in Q3 2025.
Invivyd (IVVD) has 6 years of Total Liabilities data on file, last reported at $35.3 million in Q4 2025.
- For the quarter ending Q4 2025, Total Liabilities fell 42.97% year-over-year to $35.3 million; the trailing twelve-month figure through Dec 2025 stood at $35.3 million (down 42.97% YoY), and the FY2025 full-year result was $35.3 million, down 42.97% from the prior year.
- Total Liabilities for Q4 2025 stood at $35.3 million, down from $46.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $103.4 million in Q1 2021 and bottomed at $23.8 million in Q1 2023.
- The 5-year median for Total Liabilities is $46.8 million (2022), against an average of $51.4 million.
- The widest annual swing landed in 2021, when Total Liabilities jumped 374.45%; it then plunged 75.42% in 2023.
- A 5-year view of Total Liabilities shows it stood at $62.1 million in 2021, then sank by 56.18% to $27.2 million in 2022, then soared by 90.14% to $51.7 million in 2023, then gained by 19.85% to $62.0 million in 2024, then plunged by 42.97% to $35.3 million in 2025.
- The last three Total Liabilities figures came in at $35.3 million (Q4 2025), $46.1 million (Q3 2025), and $46.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 35.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.34 Mn |
| Sep 30, 2025 | 46.09 Mn |
| Jun 30, 2025 | 46.35 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.71 Mn |
| Sep 30, 2023 | 28.42 Mn |
| Jun 30, 2023 | 33.85 Mn |
| Mar 31, 2023 | 23.82 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Sep 30, 2021 | 53.06 Mn |
| Jun 30, 2021 | 37.91 Mn |
| Mar 31, 2021 | 103.36 Mn |
| Dec 31, 2020 | 13.08 Mn |